Related Experiment Video
Updated: Jul 4, 2026

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
Single-center experience with the TandemHeart percutaneous ventricular assist device to support patients undergoing
Wael Al-Husami1, Frederick Yturralde, Guru Mohanty
1Lahey Clinic Medical Center, 41 Mall Rd. Burlington, MA 01805, USA. thomas_piemonte@lahey.org
Insights
The TandemHeart percutaneous ventricular assist device (THpVAD) safely supported high-risk percutaneous coronary intervention (PCI) in patients with complex coronary lesions and reduced ejection fraction. This approach enhanced procedural success and patient safety during complex PCI procedures.
Area of Science:
- Cardiology
- Interventional Cardiology
- Medical Devices
Background:
- Patients with severely depressed left ventricle systolic function and complex coronary lesions face high risks during percutaneous coronary intervention (PCI).
- Complex coronary lesions include multivessel disease, left main disease, calcified lesions, and bypass graft disease.
- These patients often require maximal hemodynamic support to prevent circulatory collapse during high-risk PCI.
Purpose of the Study:
- To evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device (THpVAD) for hemodynamic support during high-risk PCI.
- To assess the THpVAD's ability to enhance procedural success and patient safety in a high-risk patient cohort.
Main Methods:
- The study involved 6 patients with severely depressed left ventricle systolic function undergoing high-risk PCI between December 2005 and May 2007.
- The TandemHeart percutaneous ventricular assist device (THpVAD) was implanted in all patients to provide hemodynamic support.
- Procedures included multivessel PCI, unprotected left main PCI, and bypass graft PCI, with some requiring rotational atherectomy.
Main Results:
- The THpVAD was successfully implanted in all 6 patients (100% success rate).
- Five out of 6 patients (83%) survived at 30 days post-procedure; one patient died due to multiorgan failure.
- Device removal by a vascular surgeon was performed without complications.
Conclusions:
- Clinical experience with the TandemHeart pVAD demonstrated safe, efficient, and effective hemodynamic support via a percutaneous route.
- The THpVAD is a viable option for enhancing safety and success in high-risk PCI procedures.
- Percutaneous ventricular assist devices can mitigate risks associated with complex coronary interventions in vulnerable patients.
Unlabelled:
We describe our experience of patients, from December 2005 through May 2007 who underwent percutaneous coronary intervention (PCI) with severely depressed left ventricle systolic function and complex coronary lesions. The complex coronary lesions included multiple vessel coronary artery disease, left main (LM) coronary artery disease, calcified coronary lesions and bypass graft disease. All patients were clinically assessed to be at too high of a risk for circulatory collapse without maximal hemodynamic support while they underwent high-risk PCI. The TandemHeart percutaneous ventricular assist device (THpVAD) may be able to provide the necessary circulatory support required to enhance procedural success and patient safety during high-risk PCI.
Methods And Results:
We implanted the THpVAD in 6 patients who underwent high-risk PCI. There was unanimity among several physicians in our institution that each patient was an exceptionally high risk for circulatory collapse due to the anticipated procedural complexity. The average ejection fraction was 33% (range 15-65%). Five of the patients were considered to be at an unacceptably high risk for coronary artery bypass surgery. All 6 patients underwent multivessel PCI. Five of the 6 underwent unprotected LM PCI. One patient of the 5 underwent vein-graft PCI as well as a debulking procedure with rotational atherectomy and PCI of the LM. We had a 100% success rate with implantation of the THpVAD. Five of the 6 patients were alive at 30 days post procedure. One patient died 3 days after the procedure due to multiorgan failure. A vascular surgeon performed the removal of the devices with no associated complications.
Conclusions:
Our clinical experiences with the TandemHeart pVAD demonstrated that hemodynamic support could be achieved safely, efficiently and effectively by way of a percutaneous route in anticipation of high-risk PCI.
Related Concept Videos
Cardiac Catheterization II: Right Heart Catheterization
Cardiac Catheterization III: Left Heart Catheterization
Cardiac Catheterization I: Pre-Procedure Overview
Cardiac Catheterization IV: Nursing Management
Cardiomyopathy V: Interprofessional Care
Heart Failure VI: Adjunct Therapies
